Form 8-K

8-K — SPLASH BEVERAGE GROUP, INC.

Accession: 0001731122-26-001020

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001553788

SIC: 2080 (BEVERAGES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7828_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7828_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7828_8k.htm · Sequence: 1

false

0001553788

2026-08-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 5, 2026

SPLASH

BEVERAGE GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40471

34-1720075

(State or other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1112 N. Flagler Drive

Fort Lauderdale,

Florida

33304

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code: (954) 648-7238

(Former name or former address, if changed since last

report.): n/a

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange

Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of

the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SBEV

NYSE American LLC

Item 7.01 Regulation FD Disclosure

On August 5, 2026, the Company issued a press release

announcing its entry into the Collaboration Agreement with Lupvindol Biosciences Ltd. for the development and advancement of CannEpil®

for veterinary uses. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)

or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of

the Company under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

Description

99.1

Press Release dated August 5, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

SIGNATURES

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

SPLASH BEVERAGE GROUP, INC.

Date: August 5, 2026

By:

/s/ Brady Cobb

Name:

Brady Cobb

Title:

Interim Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7828_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

SPLASH BEVERAGE GROUP PARTNERS WITH VETERAN CANNABINOID DRUG-DEVELOPMENT

TEAM TO ADVANCE CANNEPIL® THROUGH FDA VETERINARY PATHWAY

Collaboration with Lupvindol Biosciences will initially target companion-animal

oncology and chronic pain management

Splash retains ownership of resulting data, intellectual property and commercialization

rights

FORT LAUDERDALE, Fla., August 5, 2026 — Splash Beverage Group, Inc.

(NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has entered into a strategic development

and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical

product for companion-animal oncology and chronic pain management.

The milestone-driven program is designed to advance CannEpil through the

U.S. Food and Drug Administration’s Center for Veterinary Medicine, beginning with the Investigational New Animal Drug (“INAD”)

process and progressing toward potential conditional approval pursuant to Section 571 of the Federal Food, Drug, and Cosmetic Act (“Conditional

Approval”). Canine applications are expected to represent the initial development focus.

Lupvindol will lead the scientific, product-development and FDA regulatory

activities, including preparation of the INAD submission, development of an FDA-acceptable product development plan, study design and

oversight, regulatory correspondence and preparation of a potential Conditional Approval submission.

Splash will provide milestone-based funding and lead commercialization

strategy, strategic partnering and capital-markets activities. Importantly, Splash will own the medical technology, study data, regulatory

submissions and foreground intellectual property generated through the collaboration and will retain control over future licensing and

commercialization decisions.

“This collaboration converts our expanded CannEpil rights into a

defined and capital-efficient FDA development program,” said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group.

“Our objective is to build a differentiated cannabinoid health sciences platform by pairing high-quality intellectual property with

experienced scientific leadership, disciplined regulatory execution and global commercial capabilities.”

“The Lupvindol team has helped advance cannabinoid medicines from

development through FDA approval and commercialization. By combining that experience with Splash’s exclusive global CannEpil rights,

we believe we have assembled the assets and leadership necessary to pursue a significant opportunity in companion-animal health while

preserving Splash’s ownership of the value created through the program.”

EXPERIENCED CANNABINOID PHARMACEUTICAL LEADERSHIP

The program will be led by Hunter Land, Ph.D., Chief Executive Officer

of Lupvindol Biosciences, a pharmaceutical research and development executive with more than two decades of experience across multiple

therapeutic areas.

Dr. Land was GW Pharmaceuticals’ first full-time U.S. research and

development employee and played an important role in the development of Epidiolex®, the first FDA-approved plant-derived cannabinoid

medicine, as well as Sativex®. His experience includes cannabinoid pharmaceutical development, clinical protocol design, regulatory

strategy and commercialization planning.

The broader Lupvindol team brings experience in FDA regulatory pathways,

cannabinoid science, preclinical and clinical study design, product development and commercialization.

“Having participated in the development of Epidiolex®, I have

seen firsthand how rigorous science, disciplined execution and thoughtful regulatory engagement can transform cannabinoid research into

approved pharmaceutical products,” said Dr. Land.

“CannEpil represents a differentiated pharmaceutical cannabinoid

platform that we believe warrants evaluation through the FDA’s veterinary regulatory framework. Our team looks forward to working

with Splash to generate the scientific and clinical evidence required to support potential approval and commercialization in companion-animal

oncology and chronic pain management.”

CAPITAL-EFFICIENT DEVELOPMENT MODEL

The agreement aligns Splash’s investment with measurable regulatory

progress through an initial payment followed by milestone payments tied to opening the INAD, completing the product development plan,

advancing FDA submissions and achieving Conditional Approval or an earlier licensing transaction.

Lupvindol will absorb the annual FDA sponsor fee through Conditional Approval,

unless the parties agree to transfer sponsorship. Splash will fund any FDA-required pilot study subject to an agreed development plan

and contractual funding cap.

Following a designated FDA submission milestone, Splash will evaluate regulatory

feedback, remaining development requirements and interest from potential animal-health pharmaceutical partners before determining the

next phase of the program.

Splash will retain lead responsibility for commercialization and may elect

to partner with an established animal-health pharmaceutical company or pursue direct commercialization based on the regulatory and commercial

data available at that time.

For additional information regarding the collaboration agreement, including

an overview of material terms and a copy of the agreement as an exhibit, investors should review the Company’s Current Report on

Form 8-K filed with the Securities and Exchange Commission on August 4, 2026.

The Company licenses CannEpil from Argent Biopharma Limited pursuant to

an Exclusive License Agreement dated July 6, 2026, as amended on July 27, 2026.

COMPANION-ANIMAL HEALTH OPPORTUNITY

The global veterinary pain-management market was valued at approximately

$2.6 billion in 2024 and is projected to reach approximately $3.8 billion by 2030. Companion-animal oncology also represents a significant

unmet need. The Veterinary Cancer Society estimates that one in four dogs will develop cancer, while the National Cancer Institute estimates

approximately six million new canine cancer diagnoses annually in the United States.

“Splash is executing a disciplined strategy to build a diversified

cannabinoid health sciences platform by commercializing existing international pharmaceutical assets, advancing FDA-regulated veterinary

and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands for global markets,” Cobb said.

“We have secured the asset, expanded its licensed field and now engaged

an experienced cannabinoid drug-development team to execute the veterinary program. Our focus is achieving measurable regulatory and commercial

milestones.”

CannEpil has not been approved by the FDA for veterinary use. The indications,

study designs, regulatory requirements, costs and development timeline will be determined through engagement with the FDA. There can be

no assurance that CannEpil will receive Conditional Approval, full approval or any other regulatory authorization.

About Lupvindol Biosciences Ltd.

Lupvindol Biosciences Ltd. is a pharmaceutical and bioscience development

company with expertise in cannabinoid-based therapeutics and U.S. FDA regulatory pathways. The company is led by Hunter Land, Ph.D., whose

experience includes participation in the development of Epidiolex® and Sativex® at GW Pharmaceuticals.

About CannEpil®

CannEpil® is a proprietary pharmaceutical-grade formulation comprising

cannabidiol and tetrahydrocannabinol isolates in a liquid solution manufactured under European Union Good Manufacturing Practice standards.

CannEpil was originally developed for drug-resistant epilepsy in humans and has previously been made accessible through certain physician-directed

and special-access pathways outside the United States.

About Splash Beverage Group, Inc.

Splash Beverage Group, Inc. (NYSE American: SBEV) is a publicly traded

company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming a cannabinoid health,

wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions, and other platform-building

initiatives.

More Information

Splash Beverage Group

Contact Information

Splash Beverage Group

Info@SplashBeverageGroup.com

Media Contact

Angela Gorman

AMWPR

angela@amwpr.com

917-348-0083

Forward-Looking Statements

This press release contains forward-looking statements, including statements

regarding CannEpil’s veterinary development; potential oncology and chronic pain indications; the INAD and Conditional Approval

processes; anticipated studies, FDA interactions and regulatory submissions; potential licensing and commercialization arrangements; and

Splash’s broader business strategy.

Forward-looking statements involve risks and uncertainties that could cause

actual results to differ materially, including Splash’s ability to raise the necessary capital to finance the program, satisfy its

contractual obligations including our ability to maintain the license under the license agreement for the CannEpil product on which the

collaboration described herein depends, complete required studies, establish product safety and efficacy, obtain regulatory authorization,

protect intellectual property and the risk that competitors market the same or similar products, and execute commercialization or strategic-partnering

arrangements, and the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less

than expected or projected. There can be no assurance that an INAD will be opened, any development milestone will be achieved, CannEpil

will receive regulatory approval or any initiative will generate revenue.

Additional risks are described in Splash’s filings with the Securities

and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and the Final Prospectus on Form

424B3 filed on June 26, 2026. Splash undertakes no obligation to update forward-looking statements except as required by law.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity File Number

001-40471

Entity Registrant Name

SPLASH

BEVERAGE GROUP, INC.

Entity Central Index Key

0001553788

Entity Tax Identification Number

34-1720075

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1112 N. Flagler Drive

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33304

City Area Code

(954)

Local Phone Number

648-7238

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

SBEV

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration